Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Bifidobacterium Lactis Supplementation on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients Receiving Immunotherapy (Nivolumab)

NCT06428422 is registered in ClinicalTrials.gov with Necmettin Erbakan University as lead sponsor.

NCT NCT06428422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06428422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Bifidobacterium Lactis Supplementation on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients Receiving Immunotherapy (Nivolumab)
Lead sponsor
Necmettin Erbakan University
Phase
Not applicable
Overall status
Recruiting
Start date
August 12, 2024
Completion date
December 20, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer